Journal of Nanobiotechnology · 2022 · 22 citations · 24 references
Life SciencesImmunologyInfectious DiseasesImmunizationInnate ImmunityVaccinologyNanomedicineNanoparticle DesignNanoparticle FormulationsTuberculosis VaccinationVaccine DeliveryVaccine FormulationEffector T Cell ActivationImmunization With Bacille Calmette-guérinMycobacterium Tuberculosis InfectionNanoformulated VaccinesNanoparticle Vaccine DeliveryNanoparticle Vaccine FormulationsNanoparticle Vaccine PlatformsPreventive Vaccination
Tuberculosis (TB), induced by Mycobacterium tuberculosis (Mtb) infection, remains a top killer among infectious diseases. While Bacillus Calmette-Guerin (BCG) is the sole TB vaccine, the clumped-clustered features of BCG in intradermal immunization appear to limit both the BCG protection efficacy and the BCG vaccination safety. We hypothesize that engineering of clumped-clustered BCG into nanoscale particles would improve safety and also facilitate the antigen-presenting-cell (APC)'s uptake and the following processing/presentation for better anti-TB protective immunity. Here, we engineered BCG protoplasts into nanoscale membraned BCG particles, termed as "BCG-Nanocage" to enhance the anti-TB vaccination efficiency and safety. BCG-Nanocage could readily be ingested/taken by APC macrophages selectively; BCG-Nanocage-ingested macrophages exhibited better viability and developed similar antimicrobial responses with BCG-infected macrophages. BCG-Nanocage, like live BCG bacilli, exhibited the robust capability to activate and expand innate-like T effector cell populations of Vγ2+ T, CD4+ T and CD8+ T cells of rhesus macaques in the ex vivo PBMC culture. BCG-Nanocage immunization of rhesus macaques elicited similar or stronger memory-like immune responses of Vγ2Vδ2 T cells, as well as Vγ2Vδ2 T and CD4+/CD8+ T effectors compared to live BCG vaccination. BCG-Nanocage- immunized macaques developed rapidly-sustained pulmonary responses of Vγ2Vδ2 T cells upon Mtb challenge. Furthermore, BCG- and BCG-Nanocage- immunized macaques, but not saline controls, exhibited undetectable Mtb infection loads or TB lesions in the Mtb-challenged lung lobe and hilar lymph node at endpoint after challenge. Thus, the current study well justifies a large pre-clinical investigation to assess BCG-Nanocage for safe and efficacious anti-TB vaccination, which is expected to further develop novel vaccines or adjuvants.
24
Prevention of tuberculosis in macaques after intravenous BCG immunization
Patricia A. Darrah, Joseph J. Zeppa, Pauline Maiello et al. · Nature · 2020 · 604 citations · Full text
Adaptive Immune Response of Vγ2Vδ2 <sup>+</sup> T Cells During Mycobacterial Infections
Yun Shen, D. J. Zhou, Liyou Qiu et al. · Science · 2002 · 384 citations · Full text